STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1739 by analyst upside · 2026-08-12
LMAT
LeMaitre Vascular, Inc.
Healthcare · Market Cap $2B · P/E 29.0x
ANALYST PRICE TARGET
+32.8%
implied upside to consensus target
Current Price $82.84
Consensus Target $110.0
Bull Target $132.0
Bear Target $94.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
2
Hold
4
Sell
0
52-Week Low $78.65
52-Week High $118.01
YTD Return +3.8%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 29.0x
Forward P/E 25.9x
EPS (TTM) $2.86
PEG Ratio 2.35
Dividend Yield 1.23%
Revenue (TTM) $262M
Profit Margin 25.0%
52-WEEK RANGE
52-Week Low $78.65
52-Week High $118.01
Current Price $82.84
Bear Target $94.0
Bull Target $132.0
● Now $82.84 ● Target $110.0
TRADING DATA
Avg Volume 364K
YTD Return +3.8%
Analyst Count 7
Consensus Buy
Upside to Target +32.8%
Last Updated 2026-08-12

ANALYST SUMMARY

LeMaitre Vascular, Inc. (LMAT) is currently trading at $82.84 with a Wall Street consensus price target of $110.0, implying potential upside of 32.8% over the next 12 months. 7 analysts currently cover LMAT, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $132.0, while the most cautious has a target of $94.0.

LMAT operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 3.8% year-to-date and is currently trading near the lower end of its 52-week range of $78.65 – $118.01.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LMAT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barrington Research - Reiterated
Outperform → Outperform 2026-06-03 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-05-06 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-06 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-05-06 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-02-26 Building track record
Roth Capital reit
Buy → Buy 2026-02-26 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-02-26 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-02-26 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
16/30
Consensus clarity
21/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →